TY - JOUR T1 - Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation JF - Bone Marrow Transplantation Y1 - 1998 A1 - Arbona,C. A1 - Prosper,F. A1 - Benet,I. A1 - Mena,F. A1 - Solano,C. A1 - Garcia-Conde,J. KW - *Granulocyte Colony-Stimulating Factor / ad [Administration & Dosage] KW - *Hematopoietic Stem Cell Mobilization / mt [Methods] KW - *Hematopoietic Stem Cell Transplantation KW - Adolescent KW - Adult KW - Aged KW - Blood Cell Count / de [Drug Effects] KW - Blood Component Removal / ae [Adverse Effects] KW - Child KW - Drug Administration Schedule KW - Female KW - Hematopoietic Stem Cell Mobilization / ae [Adverse Effects] KW - Humans KW - Male KW - Middle Aged KW - Transplantation, Homologous AB - Despite the wide use of G-CSF for mobilization of PBPC the best dose and schedule of G-CSF has not been definitively established. In this study we have compared three different schedules of G-CSF for mobilization of PBPC in normal donors including a single daily dose of 10 microg/kg/day for 5 days (21 donors) and doses of 6 (21 donors) or 8 microg/kg/12 h (6 donors) for 5 days. We demonstrate that G-CSF at doses of 6 and 8 microg/kg/12 h mobilizes significantly more CD34+ cells/ml of blood (83.3 +/- 6.7 and 121 +/- 6.9, respectively) than 10 microg/kg/day (71.6 +/- 6.5). Mobilization with 6 or 8 microg/kg/12 h of G-CSF was also associated with collection of significantly more CD34+ cells in comparison with 10 microg/kg/24 h (2.24 +/- 1.2 and 2.46 +/- 1.22 vs 1.15 +/- 0.8 CD34+ cells/kg of donor/blood volume). PBPC collection was associated with a significant decrease in platelet count which was not significantly different between the three groups. Ten days after the last PBPC collection platelet counts were within normal limits while there was a decrease in WBC and ANC. We conclude that G-CSF administered every 12 h at doses of 6 microg/kg provides better CD34+ cell yield than 10 microg/kg once a day in normal donors which may translate into a decrease in the number of aphereses required to obtain enough numbers of CD34+ cells for allogeneic PBPC transplant. VL - 22 CP - 1 N1 - HPC ID - 90 ER -